Comparative Pharmacology
Head-to-head clinical analysis: TIMOLOL MALEATE versus TRANDATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIMOLOL MALEATE versus TRANDATE.
TIMOLOL MALEATE vs TRANDATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective beta-adrenergic receptor antagonist (beta-blocker). Competitively blocks beta1 and beta2 receptors, reducing heart rate, myocardial contractility, and cardiac output. Also decreases aqueous humor production in the eye by blocking beta2 receptors on ciliary epithelium.
Competitive antagonist at beta-1 and beta-2 adrenergic receptors; also blocks alpha-1 adrenergic receptors, causing vasodilation.
Systemic: 1 drop of 0.25% or 0.5% solution in affected eye(s) twice daily. Additional indication: 0.5% gel-forming solution once daily. Oral: 10 mg twice daily, may increase to 20 mg twice daily if needed.
Initial: 100 mg orally twice daily, titrate to 200-400 mg twice daily; maximum 2400 mg/day. Alternatively, 20 mg IV bolus over 2 minutes, then 40-80 mg IV at 10-minute intervals as needed; IV infusion: 2 mg/min, titrate to response.
None Documented
None Documented
2-3 hours (terminal); prolonged in hepatic impairment
Terminal elimination half-life is approximately 6-8 hours in healthy individuals, but may be prolonged in patients with hepatic impairment or severe renal dysfunction (up to 12-16 hours).
Renal: 20% unchanged; biliary/fecal: 80% as metabolites
Labetalol is extensively metabolized in the liver via glucuronidation; less than 5% of the dose is excreted unchanged in urine. Approximately 55-60% of metabolites are excreted renally, and about 30% in feces via biliary secretion.
Category A/B
Category C
Beta-Blocker
Beta-Blocker